Background: Many studies suggest that the virus-like particles are required for the infection of Creutzfeldt-Jakob disease (CJD). Objective: To determine the relationship between BK polyomavirus (BKV) and sporadic CJD. Materials and Methods: We investigated the prevalence of BKV in urine samples from 94 sporadic CJD patients and 54 other neurological disease (OND) patients using polymerase chain reaction. Results: BKV DNA was detected in 16 (17%) and 9 (16.7%) urine samples from sporadic CJD and OND patients, respectively. There was no significant difference in the incidence of BKV infection between Korean sporadic CJD and OND patients (p = 0.9558). In order to investigate the genotypes of BKV, we analyzed 22 BKV isolates obtained from Korean patients by DNA sequencing and nucleotide sequence analysis. Three distinct subtypes, namely I, III, and IV, were found in 66.7, 22.2, and 11.1% of 9 BKV isolates from OND patients, whereas subtypes I and IV were detected in 76.9 and 23.1% of 13 BKV isolates from sporadic CJD patients. Interestingly, subtype III was not detected in sporadic CJD patients. Significant differences in the frequency of BKV genotypes were not observed between sporadic CJD and OND patients. Conclusions: These results indicate that BKV may not play an important role in the pathogenesis of prion diseases.

Keywords:
Polyomavirus, Genotypes, BK virus, Prion disease, Creutzfeldt-Jakob disease, Phylogenetic tree
1.
Prusiner SB: Molecular biology of prion disease. Science 1991;252:1515-1522.
2.
Kim NH, Choi JK, Jeong BH, Kim JI, Kwon MS, Carp RI, Kim YS: Effect of transition metals (Mn, Cu, Fe) and deoxycholic acid (DA) on the conversion of PrPC to PrPres. FASEB J 2005;19:783-785.
3.
Manuelidis L: Nuclease-resistant circular DNAs copurify with infectivity in scrapie and CJD. J Neurovirol 2011;17:131-145.
4.
David-Ferreira JF, David-Ferreira KL, Gibbs CJ Jr, Morris JA: Scrapie in mice: ultrastructural observations in the cerebral cortex. Proc Soc Exp Biol Med 1968;127:313-320.
5.
Bignami A, Parry HB: Aggregations of 35-nanometer particles associated with neuronal cytopathic changes in natural scrapie. Science 1971;171:389-390.
6.
Sklaviadis T, Dreyer R, Manuelidis L: Analysis of Creutzfeldt-Jakob disease infectious fractions by gel permeation chromatography and sedimentation field flow fractionation. Virus Res 1992;26:241-254.
7.
Narang HK: Evidence that single-stranded DNA wrapped around the tubulofilamentous particles termed ‘nemaviruses' is the genome of the scrapie agent. Res Virol 1998;149:375-382.
8.
Manuelidis L: Transmissible encephalopathies: speculations and realities. Viral Immunol 2003;16:123-139.
9.
Liberski PP, Jeffrey M: Tubulovesicular structures-the ultrastructural hallmark for transmissible spongiform encephalopathies or prion diseases. Folia Neuropathol 2004;42(suppl B):96-108.
10.
Manuelidis L, Yu ZX, Barquero N, Mullins B: Cells infected with scrapie and Creutzfeldt-Jakob disease agents produce intracellular 25-nm virus-like particles. Proc Natl Acad Sci USA 2007;104:1965-1970.
11.
Manuelidis L: A 25-nm virion is the likely cause of transmissible spongiform encephalopathies. J Cell Biochem 2007;100:897-915.
12.
Brecher K, Stopa EG, Kenney K: Concurrent herpes simplex virus encephalitis and Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 1998;64:418-419.
13.
Pollak L, Shabazov E, Mendlovic S, Rabey MJ: Herpes simplex encephalitis as an initial presentation of Creutzfeldt-Jakob disease. Isr Med Assoc J 2008;10:392-394.
14.
Jacobi C, Arlt S, Reiber H, Westner I, Kretzschmar HA, Poser S, Zerr I: Immunoglobulins and virus-specific antibodies in patients with Creutzfeldt-Jakob disease. Acta Neurol Scand 2005;111:185-190.
15.
Cordeiro Y, Machado F, Juliano L, Juliano MA, Brentani RR, Foguel D, Silva JL: DNA converts cellular prion protein into the β-sheet conformation and inhibits prion peptide aggregation. J Biol Chem 2001;276:49400-49409.
16.
Lee KH, Jeong BH, Jin JK, Meeker HC, Kim JI, Carp RI, Kim YS: Scrapie infection activates the replication of ecotropic, xenotropic, and polytropic murine leukemia virus (MuLV) in brains and spinal cords of senescence-accelerated mice: implication of MuLV in progression of scrapie pathogenesis. Biochem Biophys Res Commun 2006;349:122-130.
17.
Jeong BH, Lee YJ, Carp RI, Kim YS: The prevalence of human endogenous retroviruses in cerebrospinal fluids from patients with sporadic Creutzfeldt-Jakob disease. J Clin Virol 2010;47:136-142.
18.
Elsner C, Dörries K: Evidence of human polyomavirus BK and JC infection in normal brain tissue. Virology 1992;191:72-80.
19.
Zerr I, Pocchiari M, Collins S, Brandel JP, de Pedro Cuesta J, Knight RS, Bernheimer H, Cardone F, Delasnerie-Lauprêtre N, Cuadrado Corrales N, Ladogana A, Bodemer M, Fletcher A, Awan T, Ruiz Bremón A, Budka H, Laplanche JL, Will RG, Poser S: Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000;55:811-815.
20.
Jeong BH, Jeon YC, Lee YJ, Cho HJ, Park SJ, Chung DI, Kim J, Kim SH, Kim HT, Choi EK, Choi KC, Carp RI, Kim YS: Creutzfeldt-Jakob disease with the V203I mutation and M129V polymorphism of the prion protein gene (PRNP) and a 17-kDa prion protein fragment. Neuropathol Appl Neurobiol 2010;36:558-563.
21.
Jeong BH, Lee KH, Lee YJ, Yun J, Park YJ, Cho HJ, Kim YH, Cho YS, Choi EK, Carp RI, Kim YS: Absence of association between two HECTD2 polymorphisms and sporadic Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 2011;31:146-151.
22.
Yun J, Jin HT, Lee YJ, Choi EK, Carp RI, Jeong BH, Kim YS: The first report of RPSA polymorphisms, also called 37/67 kDa LRP/LR gene, in sporadic Creutzfeldt-Jakob disease. BMC Med Genet 2011;12:108.
23.
Jin L, Gibson PE, Booth JC, Clewley JP: Genomic typing of BK virus in clinical specimens by direct sequencing of polymerase chain reaction products. J Med Virol 1993;41:11-17.
24.
De Bruyn G, Limaye AP: BK virus-associated nephropathy in kidney transplant recipients. Rev Med Virol 2004;14:193-205.
25.
Kinnaird AN, Anstead GM: Hemorrhagic cystitis and possible neurologic disease from BK virus infection in a patient with AIDS. Infection 2010;38:124-127.
26.
Knowles WA: Propagation and assay of BK virus. Methods Mol Biol 2001;165:19-31.
27.
Chesters PM, Heritage J, McCance DJ: Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. J Infect Dis 1983;147:676-684.
28.
Luo C, Bueno M, Kant J, Martinson J, Randhawa P: Genotyping schemes for polyomavirus BK, using gene-specific phylogenetic trees and single nucleotide polymorphism analysis. J Virol 2009;83:2285-2297.
29.
Yogo Y, Zhong S, Suzuki M, Shibuya A, Kitamura T: Occurrence of the European subgroup of subtype I BK polyomavirus in Japanese-Americans suggests transmission outside the family. J Virol 2007;81:13254-13258.
30.
Takasaka T, Goya N, Tokumoto T, Tanabe K, Toma H, Ogawa Y, Hokama S, Momose A, Funyu T, Fujioka T, Omori S, Akiyama H, Chen Q, Zheng HY, Ohta N, Kitamura T, Yogo Y: Subtypes of BK virus prevalent in Japan and variation in their transcriptional control region. J Gen Virol 2004;85:2821-2827.
31.
Ikegaya H, Saukko PJ, Tertti R, Metsärinne KP, Carr MJ, Crowley B, Sakurada K, Zheng HY, Kitamura T, Yogo Y: Identification of a genomic subgroup of BK polyomavirus spread in European populations. J Gen Virol 2006;87:3201-3208.
32.
Zheng HY, Nishimoto Y, Chen Q, Hasegawa M, Zhong S, Ikegaya H, Ohno N, Sugimoto C, Takasaka T, Kitamura T, Yogo Y: Relationships between BK virus lineages and human populations. Microbes Infect 2007;9:204-213.
33.
Nishimoto Y, Zheng HY, Zhong S, Ikegaya H, Chen Q, Sugimoto C, Kitamura T, Yogo Y: An Asian origin for subtype IV BK virus based on phylogenetic analysis. J Mol Evol 2007;65:103-111.
34.
Zhong S, Randhawa PS, Ikegaya H, Chen Q, Zheng HY, Suzuki M, Takeuchi T, Shibuya A, Kitamura T, Yogo Y: Distribution patterns of BK polyomavirus (BKV) subtypes and subgroups in American, European and Asian populations suggest co-migration of BKV and the human race. J Gen Virol 2009;90:144-152.
35.
Zhong S, Jeong BH, Ikegaya H, Kim YS, Xu Y, Zhu M, Chao Y, Suzuki M, Kitamura T, Homma Y, Yogo Y: Comparison of the distribution patterns of BK polyomavirus lineages among China, Korea and Japan: implications for human migrations in northeast Asia. Microbiol Immunol 2009;53:266-276.
36.
Boldorini R, Allegrini S, Miglio U, Paganotti A, Veggiani C, Mischitelli M, Monga G, Pietropaolo V: Genomic mutations of viral protein 1 and BK virus nephropathy in kidney transplant recipients. J Med Virol 2009;81:1385-1893.
37.
Stoner GL, Alappan R, Jobes DV, Ryschkewitsch CF, Landry ML: BK virus regulatory region rearrangements in brain and cerebrospinal fluid from a leukemia patient with tubulointerstitial nephritis and meningoencephalitis. Am J Kidney Dis 2002;39:1102-1112.
38.
Rollison DE, Utaipat U, Ryschkewitsch C, Hou J, Goldthwaite P, Daniel R, Helzlsouer KJ, Burger PC, Shah KV, Major EO: Investigation of human brain tumors for the presence of polyomavirus genome sequences by two independent laboratories. In J Cancer 2005;113:769-774.
39.
Jeong BH, Lee KH, Kim NH, Jin JK, Kim JI, Carp RI, Kim YS: Association of sporadic Creutzfeldt-Jakob disease with homozygous genotypes at PRNP codons 129 and 219 in the Korean population. Neurogenetics 2005;6:229-232.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.